CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Income Statement [Abstract]
Net revenues	$ 86,713	$ 61,514	$ 160,022	$ 113,639	$ 248,069
Cost of revenues	21,106	19,833	40,920	38,071	80,048
Gross profit	65,607	41,681	119,102	75,568	168,021
Operating costs and expenses:
Research, development and clinical trials	19,454	11,362	36,496	22,466	50,574
Sales and marketing	23,708	19,196	46,041	37,331	77,663
General and administrative	21,249	18,208	41,487	35,533	73,456
Total operating costs and expenses	64,411	48,766	124,024	95,330	201,693
Operating income (loss)	1,196	(7,085)	(4,922)	(19,762)	(33,672)
Financial expenses (income), net	1,239	2,860	3,610	7,713	12,270
Income (loss) before income taxes	(43)	(9,945)	(8,532)	(27,475)	(45,942)
Income taxes	1,227	5,565	4,888	8,759	17,617
Net income (loss)	$ (1,270)	$ (15,510)	$ (13,420)	$ (36,234)	$ (63,559)
Basic and diluted net income (loss) per ordinary share	$ (0.01)	$ (0.17)	$ (0.14)	$ (0.40)	$ (0.69)
Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share	96,356,317	91,331,862	95,583,802	90,658,735	91,828,043